PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?
Inhibitory properties of PD-1 receptor engagement on activated T cells are well established in physiologic and pathological contexts.In cancer, Glass Blunts the use of checkpoint blockade, such as anti-PD-1 antibodies, becomes progressively a reference treatment of a growing number of tumors.Nonetheless, it is also established that PD-1 expression